ESG Data Table

The data are basically on a non-consolidated basis.

ISO26000 Core Subject

Organizational Governance

Reported Items Unit FY2023 FY2022 FY2021
Management Structure
Executive Committee Times 10 11 11
Board of Directors Times 16 18 22
Attendance Rate of Board of Directors % 99.11 99.21 98.96
Directors Persons 9 9 9
Of Which, Outside Directors Persons 4 4 4
Of Which, Female Directors Persons 1 1 1
Amount of Remuneration and the Like Millions of Yen 215 326 392
Principal Activities of Outside Directors
Yutaka Atomi − − He attended all twenty-two (22) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily from the professional standpoint of a medical doctor.
Saeko Arai She attended all sixteen (16) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on her extensive experience as a corporate executive and from the professional standpoint of a certified public accountant. She attended all eighteen (18) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on her extensive experience as a corporate executive and from the professional standpoint of a certified public accountant. She attended all twenty-two (22) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on her extensive experience as a corporate executive and from the professional standpoint of a certified public accountant.
Nobuhiro Endo He attended fifteen (15) meetings out of the sixteen (16) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and a broad perspective as a corporate executive. He attended all eighteen (18) meeting held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and a broad perspective as a corporate executive. He attended all twenty (20) of the twenty-two (22) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive.
Minoru Usui He attended fifteen (15) meetings out of the sixteen (16) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive. He attended all eighteen (18) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive. He attended all seventeen (17) meetings held by the Board of Directors during the fiscal year under review after his assumption of office as a Director, and made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive.
Koji Fujimoto He attended all sixteen (16) meetings held by the Board of Directors during the fiscal year under review, and made statements at those meetings, primarily based on his extensive experience and broad perspective in the healthcare field at administrative organizations. He attended all fifteen (15) meetings held by the Board of Directors during the fiscal year under review after his assumption of office as a Director, and made statements at those meetings, primarily based on his extensive experience and broad perspective in the healthcare field at administrative organizations. −
Audit System
Audit & Supervisory Board Times 13 13 13
Audit & Supervisory Board Members Persons 5 5 5
Of Which, Outside Audit & Supervisory Board Members Persons 3 3 3
Amount of Remuneration and the like Millions of Yen 91 93 89
Full-Time Staff of Corporate Audits' Office Persons 1 1 1
Principal Activities of Outside Audit Supervisory Board
Junsuke Fujii − − He attended all twenty-two (22) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily based on his extensive experience and broad perspective as a corporate executive.
Yoshio Iteya He attended all sixteen (16) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily from the professional standpoint of an attorney. He attended seventeen (17) meetings out of the eighteen (18) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily from the professional standpoint of an attorney. He attended all twenty-two (22) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily from the professional standpoint of an attorney.
Mayumi Mochizuki She attended all sixteen (16) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. She made statements at those meetings, primarily from the professional standpoint of a pharmacologist. She attended seventeen (17) meetings out of the eighteen (18) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. She made statements at those meetings, primarily from the professional standpoint as a pharmacologist. She attended eleven (11) meetings out of the seventeen (17) meetings held by the Board of Directors and eight (8) meetings out of the ten (10) meetings held by the Audit & Supervisory Board during the fiscal year under review after her assumption of office as an Audit & Supervisory Board Member. She made statements at those meetings, primarily from the professional standpoint as a pharmacologist.
Daishiro Michimori He attended all sixteen (16) meetings held by the Board of Directors and all thirteen (13) meetings held by the Audit & Supervisory Board during the fiscal year under review. He made statements at those meetings, primarily from the professional standpoints of an expert in financial and accounting affairs and of an attorney. He attended all fifteen (15) meetings held by the Board of Directors and all ten (10) meetings held by the Audit & Supervisory Board during the fiscal year under review after his assumption of office as an Audit & Supervisory Board Member. He made statements at those meetings, primarily from the professional standpoint of an expert in financial and accounting affairs and of an attorney. −
Communication about Compliance
Corporate CSR Blog Articles 4 2 3
Framework for Compliance Implementation
Periodic Report at Board of Directors Times 1 1 1
Compliance Committee Times 1 1 1
Compliance Committee of Group Companies in Japan Times 1 1 1
Compliance Committee of Group Companies outside Japan Times 1 1 1
Whistle-blowing Systems, Consultation Desks
Hotline and Desk for All Employees Systems 6 6 7
Consulted Issues Cases 25 37 41
Compliance Education and Training
Compliance Trainings for All Employees Times 7 5 2
Compliance Workshops Held at the Workplace Level for All Workplaces Times 1 1 1
Compliance Workshops Held at the Group Companies for All Group Companies Times 0 1 1
Harmful Incident Concerning Pharmaceuticals Workshops for All Employees Times 1 1 1
Information Security Training for All Employees Times 1 1 1
Stress Check for All Employees Times 1 1 1
Mental Health Manager Workshops Times 1 1 1
Mental Health Self-Care Workshops Times 1 1 1
Product Recall Training in Corporate Regulatory Compliance & Quality Assurance Division Times 1 1 1
Natural Disaster Training in Risk Management Related Divisions Times 3 3 1
R&D Ethics e-Learning for Researchers Who Are Recommended to Take the Course on the Job Times 1 1 1

Human Rights

Reported Items Unit FY2023 FY2022 FY2021
Initiative to Respect Human Rights
Human Rights Workshops for All Employees Times 1 1 1
Harmful Incident Concerning Pharmaceuticals Workshops for All Employees Times 1 1 1
Initiative to Prevent Harassment
Number of People in Charge of the General Consultation Desk Persons 2 2 2
Number of People in Charge of the Harassment Consultation Desk (Within the Company) Persons General Desk: 3
7 Working Place Desks: 17		 General Desk: 3
7 Working PlaceDesks: 17		 General Desk: 3
7 Working PlaceDesks: 17
Number of People in Charge of the Harassment Consultation Desk (Workers Union) Persons General Desk: 4
11 Working Place Desks: 11		 General Desk: 4
11 Working Place Desks: 11		 General Desk: 5
11 Working Place Desks: 11

Labour Practices

  • The social performance indicators marked with have received third-party assurance.
Reported Items Unit FY2023 FY2022 FY2021
Basic Human Resources Data
Number of Employees (Consolidated) as of March 31 Persons 4980 6250 6987
Men Persons 3099 3718 4147
Women Persons 1881 2532 2840
Proportion of Women % 37.8 40.5 40.6
Number of Employees (Non-Consolidated) as of March 31 Persons 2908 3026 3040
Men Persons 2166 2260 2292
Women Persons 742 766 748
Proportion of Women % 25.5 25.3 24.6
Proportion of Female Managers as of April 1 of the Following Fiscal Year % 13.7 14.4 16.0
Gender Wage Gap (All Workers)*1 % 81.9 81.3 −
Gender Wage Gap (Permanent Workers)*1 % 84.0 82.5 −
Gender Wage Gap (Part-Time Workers and Fixed-Term Workers)*1 % 91.3 79.0 −
MRs in Japan, including Managers Persons 1000 1140 1220
MRs in Japan, excluding Managers Persons 910 1040 1110
Average Age Years 44.3 43.8 43.4
Average Length of Continuous Employment Years 18.7 18.3 18.0
Recruitment of New Graduates Persons 48 70 64
Proportion of Women in New Graduates Recruitment % 37.5 51.4 53.1
Recruitment of Mid Career Persons 24 41 29
Proportion of Recruitment of Mid Career % 33.3 36.9 31.2
Employment Rate of Persons with Disabilities as of June 1, Every Fiscal Year % 2.61 2.34 2.34
Employee Turnover Rate of Employees Leaving for Personal Reasons % 3.96 2.67 1.68
Retention Rate of New Graduates 3 Years after Joining the Company % 81.3 87.9 94.3
Labour Union Participating Rate Eligibility Conducted by Collective Agreement Article 3-1 % 100 100 100
Total Actual Working Hours per Year Hours 1848.0 1849.5 1871.5
Average Overtime Hours per Month Hours 3.6 4.0 4.1
Average Usage of Paid Leave Days/Person 15.7 15.4 14.1
Paid Leave Acquisition Rate % 78.1 77.5 70.0
Male Employees Taking Childcare Leave*2 Persons 71 95 83
Childcare Leave Usage Rate (Male Employees)*2 % 104.4 130.1 97.6
Female Employees Taking Childcare Leave*2 Persons 31 26 51
Utilization of Shorter Working Hours for Childcare Persons 85 83 66
Utilization of Leave for Nursing Care Persons 0 1 1
Utilization of Shorter Workdays for Nursing Care Persons 3 2 1
Mental Illness Leave (≧30days) Persons 12 17 25
Health and Safety Management
Stress Check for All Employees Times 1 1 1
Mental Health Manager Workshops Times 1 1 1
Mental Health Self-Care Workshops Times 1 1 1
No-Overtime Day at Workplace Level Days/Month Established at Each Workplace Established at Each Workplace Established at Each Workplace
Whole Company No-Overtime Day Days 1 1 1
Work-Related Accident Frequency Rate (Non-Consolidated) −
    • 1.34
0.97 1.27
Work-Related Accident Frequency Rate (Non-Consolidated)
excluding Accidents Involving Business Vehicles		 −
    • 0.83
0.81 0.79
Lost-Time Injuries Frequency Rate (Non-Consolidated) −
    • 0.00
0.32 0.16
Lost-Time Injuries Frequency Rate (Non-Consolidated)
excluding Accidents Involving Business Vehicles		 −
    • 0.00
0.16 0.16
Lost-Time Injuries Frequency Rate (Consolidated) −
    • 0.17
0.44 0.22
Lost-Time Injuries Frequency Rate (Contractors) −
    • 0.00
0.00 1.36
Fatalities (Consolidated) Persons
    • 0
0 0
Fatalities (Contractors) Persons
    • 0
0 0
Communication with Employees
Employee Engagement Survey Times 1 1 1
Response Rate % 98.2 98.5 98.8
Opinions toward Management Cases 731 757 778
Proposals Made to Address Issues and/or Offer Solutions at Respective Divisions/Departments Cases 799 911 986
  • *1Regarding the gender wage gap, our wage system is based on the grade of the role (job) in which each employee is engaged, and there is no difference in base wages for male and female employees in the same grade; however, the following factors contribute to the differences in their average annual wages. Employees who do not receive their wages due to absenteeism, absence from work or temporary retirement are excluded from the calculation. Among permanent workers, the fact that the percentage of female employees in general office work positions is higher than that of male employees is the main factor in the gender wage gap. As for part time workers and fixed-term workers, the majority of them are part time workers; and, the wage levels for part time workers are lower than those for employees rehired after retirement and contract workers, due to reasons such as differences in job level and working hours. The fact that these part time workers are all female workers is a factor contributing to the gender wage gap.
  • *2The number of employees excluding seconded employees is listed.

The Environment

  • The environmental performance indicators marked with have received third-party assurance.
Reported Items Unit FY2023 FY2022 FY2021
Environmental Management
Environmental and Safety Committee Times 2 2 3
Environmental and Safety Managers' Conference Times 2 2 2
Environment, Health and Safety Audit Business units 6 4 6
Follow-up Activities for Environment, Health and Safety Audit Cases 17 8 16
Environmental Accidents Cases 0 0 0
Violation of Environmental Laws and Regulations Involving Criminal or Non-Criminal Fines Cases 0 0 0
Energy Consumption
Total Energy Consumption MWh
    • 271591
280835 261238
Non-Renewable Energy Consumption MWh 237619 246663 254219
Renewable Energy Consumption MWh
    • 33972
34172 7019
Amount of Purchased Electricity Derived from Renewable Energy Sources*1 MWh 33832 34083 6933
Amount of Generated Electricity at the Solar Power Generating Systems*2 MWh 140 89 86
CO2Emissions
Scope 1 (from Energy Sources)+Scope 2 (Market-Based)
Total Emissions 		t-CO2
    • 53920
54347 61749
Scope 1 (from Energy Sources) Emissions t-CO2
    • 27093
27829 21398
Scope 2 (Market-Based) Emissions t-CO2
    • 26827
26518 40351
Scope 3 Emissions *3 t-CO2 356214 366620 382293
Category 1 (Purchased Goods and Services)*4 t-CO2
    • 305002
310925 332970
Category 2 (Capital goods)*4 t-CO2 18623 24134 19015
Category 3 (Fuel- and Energy-Related Activities not Included in Scope 1 or Scope 2) t-CO2 15017 15048 15643
Category 4 (Upstream Transportation and Distribution) t-CO2 820 853 824
Category 5 (Waste Generated in Operations) t-CO2 4563 3655 4466
Category 6 (Business Travel) t-CO2 3375 3140 886
Category 7 (Employee Commuting) t-CO2 690 634 651
Category 8 (Upstream Leased Assets) t-CO2 − − −
Category 9 (Downstream Transportation and Distribution)*5 t-CO2 4184 5305 3344
Category 10 (Processing of Sold Products) t-CO2 − − −
Category 11 (Use of Sold Products) t-CO2 3554 2521 4065
Category 12 (End-of-Life Treatment of Sold Products) t-CO2 250 302 323
Category 13 (Downstream Leased Assets) t-CO2 136 103 106
Category 14 (Franchises) t-CO2 − − −
Category 15 (Investments) t-CO2 − − −
Amount of Water Withdrawal and Water Discharged
Total Amount of Water Withdrawal (Consolidated) t
    • 862627
847157 873171
Ground Water (Consolidated)*6 t
    • 144130
113045 55853
Third-Party Sources (Consolidated) t
    • 718497
734112 817318
Total Amount of Water Withdrawal (Non-Consolidated) t 831818 804281 814250
Ground Water (Non-Consolidated)*6 t 144130 113045 55853
Third-Party Sources (Non-Consolidated) t 687688 691236 758397
Total Amount of Water Discharged (Consolidated) t
    • 859532
843300 866398
River (Consolidated) t 617860 589817 604448
Sewerage (Consolidated) t 241672 253483 261950
Total Amount of Water Discharged (Non-Consolidated) t 831818 804281 814250
River (Non-Consolidated) t 617860 589817 604448
Sewerage (Non-Consolidated) t 213958 214464 209802
Raw Material Consumption
Raw Materials for Products (excluding Metals) t 3694 2861 3577
Raw Materials for Products (Metals) t 3 1 0
Total Amount of Product Containers and Packaging Materials t 511 590 642
Glass t 38 53 55
Plastic t 270 332 354
Paper t 203 204 234
PRTR Substances and VOC Substances Handled
PRTR Substances t 1696 958 1417
VOC Substances t 2970 2004 2452
Waste
Total Amount of Waste Generated t 7760 4757 6183
Amount Recycled t 6421 3442 4717
Recycling Rate % 83 72 76
Amount of Final Disposal t 8 14 18
Final Disposal Rate % 0.1 0.3 0.3
Amount of Hazardous Waste Generated t 6622 3603 5196
Amount of Hazardous Waste Recycled t 5768 3069 4408
PRTR Substances t 1695 930 1371
Waste Containing High Levels of PCB in Storage Units 0 0 0
Waste Containing Low Levels of PCB in Storage or in Use Units 4 4 4
Released into the Atmosphere
SOX t 0.4 0.3 0.3
NOX t 64.1 48.9 37.5
Dust Emissions t 0.3 0.2 0.2
PRTR Substances t 2.8 2.7 3.0
VOC Substances t 20.2 14.8 17.3
Released into Water Systems
BOD t 0.4 0.2 0.2
COD t 4.8 2.0 2.2
Phosphorus t 0.1 0.1 0.1
Nitrogen t 0.6 0.4 0.5
PRTR Substances t 0.0 0.0 0.0
Environmental Accounting
Environmental Investment Millions of Yen 159 137 226
Environmental Expenditure Millions of Yen 1021 698 772
Economic Effect Millions of Yen 36 3 3
Application of Environmental Conservation Systems
Green Procurement (Green Purchasing Ratio of Office Supplies) % 51 51 53
Green Logistics Initiatives 43 39 46
Green Product Development Initiatives 29 37 37
Green Facilities Design Initiatives 15 16 13
Environmental Considerations for Business Vehicles
Percentage of Business Vehicles Shifted to Hybrid Cars (excluding Cold Regions) % 100 100 100
Number of Electric Vehicles (EVs) in Our Business Vehicles Vehicles 11 11 11
Communications with Group Companies
Meeting to Exchange Information on Environment and Safety between Group Companies in Japan Times 1 1 1
Environment, Health and Safety Audits Conducted for Group Companies in Japan Companies 1 0 2
Environment, Health and Safety Audits Conducted for Group Companies outside Japan Companies 0 0 0
Biodiversity
Owls Forest Restoration Project of Kishiwada City, Osaka*7 Times/
Participants 		2/60 6/128 1/13
  • *1Including the use of Non-Fossil Certificates to reduce the CO2 emissions associated with vending machine operation (in collaboration with DyDo DRINCO, INC.'s carbon neutral initiatives).
  • *2The amount of solar power generation in FY2021 and FY2022 shows only the amount of solar power generation at the Central Research Laboratories due to measuring instrument failure at the Osaka Research Center.
  • *3In conjunction with the update of Category 9 emissions for FY2022, we are also updating the total emissions for FY2022.
  • *4In Japanese Ministry of the Environment's "The database on emissions unit values for accounting of greenhouse gas emissions, etc. by organizations throughout the supply chain" (ver. 3.3), it was (newly) specified that the consumption tax is included in the emission intensity. Therefore, we calculated the figures for FY2022 and FY2023 by taking into account the consumption tax. As for the figures for FY2021, we did not take into account the consumption tax when calculating the figures; however, we have not revised them as their impact is not significant.
  • *5CO2 emissions from pharmaceutical wholesalers in FY2023 have not been disclosed. Therefore, CO2 emissions from pharmaceutical wholesalers in FY2022 were used in the calculation of CO2 emissions in FY2023. As for the sales of pharmaceutical wholesalers and the sales of our products in pharmaceutical wholesalers, the sales in FY2023 were used. Furthermore, as the CO2 emissions for the pharmaceutical wholesalers for FY2022 have been disclosed, we have revised the CO2 emissions for FY2022 to reflect this figure in our calculations.
  • *6The figures for FY2021 do not include 18,149 tons† of groundwater that was pumped up but not used and then discharged.
    (†) Difference between raw water and treated water in the period between June and October 2021 (5 months) when groundwater use was suspended.
  • *7We refrained from the activities to prevent the spread of COVID-19 in FY2021.

Fair Operating Practices

Reported Items Unit FY2023 FY2022 FY2021
Appropriate Information Disclosure and Management
Information Security Training for All Employees Times 1 1 1
Violations of Code of Conduct
Number of Serious Compliance Violations Times 0 0 0

Consumer Issues

Reported Items Unit FY2023 FY2022 FY2021
Initiatives to Provide Stable Supplies
Plant in Japan Sites 2 2 2
Distribution Center in Japan Sites 2 2 2
Initiatives to Ensure Safety of Pharmaceuticals
Product Recall Training in Corporate Regulatory Compliance & Quality Assurance Division Times 1 1 1
Harmful Incident Concerning Pharmaceuticals Workshops for All Employees Times 1 1 1
Initiatives to Improve Access to Medicines
Responding to Demands for Development of Unapproved or Off-Label Drugs Cases 1 2 2
Collaborative Programs with Public Institutions to Control Malaria, Influenza, Antimicrobial Resistance (AMR) and Hepatitis B Projects 7 7 7
Fight against Counterfeit Pharmaceuticals in Collaboration with International Organizations Projects 1 1 1
Communication with Customers
Inquiries to the Product Information Center Cases Approx. 25,800 Approx. 30,400 Approx. 34,000

Community Involvement and Development

Reported Items Unit FY2023 FY2022 FY2021
Stakeholder Dialogue
Dialogue with Patients and Families
Inquiries to the Product Information Center Cases Approx. 1,100 Approx. 1,800 Approx. 1,900
Dialogue with Healthcare Professionals
Inquiries to the Product Information Center Cases Approx. 21,600 Approx. 26,800 Approx. 29,800
Dialogue with Collaboration Partners
Competitive Open Innovation Program Framework "PRISM"（Research Needs Presentation Ⅱ） Number of Acceptance/Number of Applications 2/8 5/59 No Recruitment
Competitive Open Innovation Program Framework "PRISM" (Research Needs Presentation, Joint Creation by Young Researchers) Number of Acceptance/Number of Applications No Recruitment No Recruitment 2/15
1 Collaboration out of PRISM
Dialogue with Shareholders
Shareholders' Meeting Times 1 1 1
Financial Results Announcement Times 4 2 2
Conference Call Times 0 2 2
Meeting with Analysts and Institutional Investors Times 115 92 103
ESG Meeting Times 0 1 1
R&D Meeting Times 0 0 1
Dialogue with Employees
Employee Engagement Survey Times 1 1 1
Response Rate % 98.1 98.5 98.8
Opinions toward Management Cases 731 757 778
Proposals Made to Address Issues and/or Offer Solutions at Respective Divisions/Departments Cases 799 911 986
Supporting Activity through Employee Participation
Educational Assistance for the Next Generation
Visiting Lectures by Employees Schools 12 14 7
Biodiversity
The Owls Forest Restoration Project at the Sumitomo Pharma Forest Times 2 6 1

Standards for Calculating Social Performance Indicators

Social Performance Indicators Scope of Aggregation Calculation Method, etc.
Work-Related Accident Frequency Rate Non-consolidated: Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan Number of deaths and injuries due to occupational accidents with or without lost workdays, excluding commuting accidents, per 1,000,000 cumulative hours worked
Work-Related Accident Frequency Rate
excluding Accidents Involving Business Vehicles		 Non-consolidated: Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan Number of deaths and injuries due to occupational accidents with or without lost workdays, excluding accidents involving business vehicles and commuting accidents, per 1,000,000 cumulative hours worked
Lost-Time Injuries Frequency Rate Non-consolidated: Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan Number of deaths and injuries due to occupational accidents with one or more lost workdays, excluding commuting accidents, per 1,000,000 cumulative hours worked
Consolidated:
<FY2021>
Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad (excluding one company for which an accident report was not available)
<FY2022 and FY2023>
Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad
Contractors: Employees of contractors (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of the Company in Japan.
Lost-time Injuries Frequency Rate
excluding Accidents Involving Business Vehicles		 Non-consolidated: Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and SMP Distribution Service Co., Ltd. in Japan Number of deaths and injuries due to occupational accidents with one or more lost workdays, excluding accidents involving business vehicles and commuting accidents, per 1,000,000 cumulative hours worked
Fatalities Consolidated:
<FY2021>
Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad (excluding one company for which an accident report was not available)
<FY2022 and FY2023>
Employees (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of Sumitomo Pharma and the Sumitomo Pharma Group's consolidated companies in Japan and abroad 		Number of deaths due to occupational accidents
Contractors: Employees of contractors (including contract employees, part-timers, temporary employees, and employees seconded to the Company) at all business sites of the Company in Japan.

Standards for Calculating Environmental Performance Indicators

●Energy Consumption

Environmental Performance Indicators Scope of Aggregation Calculation Method, Emissions Intensity, etc.
Total Energy Consumption <FY2021>
Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries' production sites (Sumitomo Pharma (Suzhou) Co., Ltd.) and their major R&D facilities (Sunovion Pharmaceuticals Inc.* and Sumitomo Pharma Oncology, Inc.*)

<FY2022 and FY2023>
Consolidated (Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries)

*Sunovion Pharmaceuticals Inc. and Sumitomo Pharma Oncology, Inc. changed their trade names to Sumitomo Pharma America, Inc. as a result of the reorganization of our U.S. group companies effective as of July 1, 2023. 		Purchased electricity#1+(purchased heat×unit calorific value+fuel consumption#2× unit calorific value)÷conversion factor for "MWh" to "GJ"#3
The unit calorific values and the types of fuel to be calculated are based on the "Act on Rationalizing Energy use and Shifting to Non-fossil Energy."
In FY2022 and FY2023, as for overseas non-production sites for which we do not have actual energy consumption data, we have made estimates based on the energy consumption at similar sites, using floor space ratios and other factors.
  • #1It includes solar power generated at our business sites.
  • #2Gasoline consumption of business vehicles includes only domestic gasoline consumption for FY2021, and all domestic and overseas gasoline consumption for FY2022 and beyond.
  • #33.6GJ/MWh
Non-Renewable Energy Consumption Amount of energy consumption derived from non-renewable energy sources out of the total energy consumption
Renewable Energy Consumption Amount of energy consumption derived from renewable energy sources out of the total energy consumption
Amount of Purchased Electricity Derived from Renewable Energy Sources Amount of renewable energy-derived electricity purchased out of the renewable energy consumption (including Non-Fossil Certificates)
Amount of Generated Electricity at the Solar Power Generating Systems Amount of solar power generated by solar power generation systems at our business sites out of the renewable energy consumption

●CO2 Emissions

Environmental Performance Indicators Scope of Aggregation Calculation Method, Emissions Intensity, etc.
Scope 1 (from Energy Sources)+Scope 2 (Market-Based) Total Emissions <FY2021>
Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries' production sites (Sumitomo Pharma (Suzhou) Co., Ltd.) and their major R&D facilities (Sunovion Pharmaceuticals Inc.* and Sumitomo Pharma Oncology, Inc.*)

<FY2022 and FY2023>
Consolidated (Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries)

*Sunovion Pharmaceuticals Inc. and Sumitomo Pharma Oncology, Inc. changed their trade names to Sumitomo Pharma America, Inc. as a result of the reorganization of our U.S. group companies effective as of July 1, 2023. 		Total of Scope 1 (from Energy Sources) and Scope 2 (Market-Based) emissions
Scope 1 (from Energy Sources) Emissions Fuel consumption#4 × fuel unit calorific value × fuel CO2 emission factor
The unit calorific values and CO2 emission factors are based on "Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System" which is provided in the "Act on Promotion of Global Warming Countermeasures." However, for city gas in Japan, we use basic emission factors or alternative value from "Emission Factors by Gas Suppliers (for the calculation of GHG emissions by specified emitters)" published by the Ministry of the environment and the Ministry of Economy, Trade and Industry of Japan.
In FY2022 and FY2023, as for overseas non-production sites for which we do not have actual fuel consumption figures, we have made estimates based on the fuel consumption at similar sites, using floor space ratios and other factors.
  • #4Gasoline consumption of business vehicles includes only domestic gasoline consumption for FY2021, and all domestic and overseas gasoline consumption for FY2022 and beyond.
Scope 2 (Market-Based) Emissions Purchased electricity#5×electricity CO2 emissions factor#6 +purchased heat × heat CO2 emissions factor#7
  • #5It includes solar power generated at our business sites.
  • #6For domestic sites, adjusted emissions factors from "Emission Factors by Power Suppliers (for the calculation of GHG emissions by specified emitters)" published by the Ministry of the Environment and the Ministry of Economy, Trade and Industry of Japan, for overseas sites, the emissions factors by country for 2019 published by the International Energy Agency (IEA). However, we use values provided by Sumitomo Chemical Co., Ltd. for sites located on the premises of Sumitomo Chemical Co., Ltd.
  • #7Values are based on "Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System" which is provided in "Act on Promotion of Global Warming Countermeasures." However, for heat in Japan, we use alternative value from "Emission Factors by Heat Suppliers (for the calculation of GHG emissions by specified emitters)" published by the Ministry of the environment and the Ministry of Economy, Trade and Industry of Japan.
    In FY2022 and FY2023, as for overseas non-production sites for which we do not have actual purchased electricity amounts, we have made estimates based on purchased electricity at similar sites, using floor space ratios and other factors.
Scope 3 Emissions Refer to each category Total of Category 1 emissions to Category 15 emissions
Ministry of the Environment DB: Ministry of the Environment's "Emission Intensity Database for Calculating Greenhouse Gas Emissions etc. of Organizations through their Supply Chains" (FY2021 emissions; Ver. 3.2 applied, FY2022 emissions; Ver. 3.3 applied, FY2023 emissions; Ver. 3.4 applied)
LCI-DB: LCI Database IDEAv2 (for calculation of supply chain GHG emissions)
Category 1 (Purchased Goods and Services) Non-consolidated Calculated by multiplying the purchase price of raw and packaging materials for products and purchased products and outsourced manufacturing costs by the emissions intensity in Japanese Ministry of the Environment database
Category 2 (Capital Goods) Consolidated basis (The Sumitomo Pharma Group including overseas subsidiaries) Calculated by multiplying the acquisition price of the fixed asset by the emissions intensity in Japanese Ministry of the Environment database
Category 3 (Fuel- and Energy-Related Activities not Included in Scope 1 or Scope 2) Non-consolidated Calculated by multiplying purchased electricity and steam by the emissions intensity in Japanese Ministry of the Environment database and purchased fuel by the emissions intensity in Carbon Footprint database or lifecycle inventory (LCI) database
Category 4 (Upstream Transportation and Distribution) Transport in Japan, on a non-consolidated basis Calculated by multiplying ton/kilometer for the transportation scenario by the emissions intensity in Japanese Ministry of the Environment database and LCI database
Category 5 (Waste Generated in Operations) Non-consolidated Calculated by multiplying the weight of waste according to type and processing method by the emissions intensity in Japanese Ministry of the Environment database
Category 6 (Business Travel) Non-consolidated Calculated by multiplying business travel expenses paid by the emissions intensity in Japanese Ministry of the Environment database
Category 7 (Employee Commuting) Non-consolidated Calculated by multiplying commuting cost according to transportation means by the emissions intensity in Japanese Ministry of the Environment database
Category 8 (Upstream Leased Assets) − −
Category 9 (Downstream Transportation and Distribution) Non-consolidated Calculated by multiplying CO2 emissions (estimate) per unit of sales in major drug wholesalers by sales of our products in drug wholesale segment
Category 10 (Processing of Sold Products) − −
Category 11 (Use of Sold Products) Non-consolidated Calculated by multiplying HFC amount in pharmaceutical MDIs (metered dose inhalers) sold by GWP
Category 12 (End-of-Life Treatment of Sold Products) Non-consolidated Calculated by multiplying the weight of the container and packaging according to material based on "Act on the Promotion of Sorted Collection and Recycling of Containers and Packaging ” by the emissions intensity in Japanese Ministry of the Environment database
Category 13 (Downstream Leased Assets) Non-consolidated Calculated by multiplying the energy consumption of the building asset owned and rented out by the conversion factors based on " Greenhouse Gas Emissions Accounting, Reporting, and Disclosure System" which is provided in "Act on Promotion of Global Warming Countermeasures"
Category 14 (Franchises) − −
Category 15 (Investments) − −

●Amount of Water Withdrawal and Water Discharged

Environmental Performance Indicators Scope of Aggregation Calculation Method
Total Amount of Water Withdrawal (Consolidated) Consolidated (Sumitomo Pharma Co., Ltd., consolidated subsidiaries in Japan, overseas consolidated subsidiaries)
However, small offices such as branches and business offices are excluded. In addition, overseas consolidated subsidiaries that do not have production sites or major research facilities are excluded from the scope because they have only small offices. 		Total amount of water withdrawal of ground water and third-party sources (tap water, industrial water and pure water)
Total Amount of Water Discharged (Consolidated) Total amount of water discharged to rivers and to sewerage.
*As for sites that do not measure the amount of water discharged, the amount of water withdrawal is considered as the water discharged.
Total Amount of Water Withdrawal (Non-Consolidated) Non-consolidated (Only Sumitomo Pharma Co., Ltd.)
However, small offices such as branches and business offices are excluded. 		Total amount of water withdrawal of ground water and third-party sources (tap water, industrial water and pure water)
Total Amount of Water Discharged (Non-Consolidated) Total amount of water discharged to rivers and to sewerage.
*As for sites that do not measure the amount of water discharged, the amount of water withdrawal is considered as the water discharged.

●Raw Material Consumption

Environmental Performance Indicators Scope of Aggregation Calculation Method
Raw Materials for Products (excluding Metals) Non-consolidated Amount of consumed raw materials for products (excluding metals)
Raw Materials for Products (Metals) Amount of consumed raw materials for products (metals)
Product Containers and Packaging Materials Total amount of product containers and packaging materials used for products sold in Japan

●PRTR Substances and VOC Substances

Environmental Performance Indicators Scope of Aggregation Calculation Method
PRTR Substances Non-consolidated Amount of PRTR substances handled for which we submitted reports under the Japanese Act on Confirmation, etc. of Release Amounts of Specific Chemical Substances in the environment and Promotion of Improvements to the Management Thereof (PRTR Law)
VOC Substances Total amount of substance annually handled in quantities of 1 ton or more, out of 55 substances*
*The number of substances excluding PRTR substances, out of 101 volatile organic compounds (VOCs), i.e. the 100 major VOCs listed by the Ministry of the Environment plus n-propyl alcohol

●Waste

Environmental Performance Indicators Scope of Aggregation Calculation Method
Total Amount of Waste Generated Non-consolidated
However, branches and business offices are excluded.		 Total amount of by-products and other unwanted materials generated as a result of our normal business activities (including valuable resources)
Amount Recycled Amount of waste reused, recycled, or converted to valuable resources out of the total amount of waste generated
Recycling Rate Percentage of amount of waste recycled to the total amount of waste generated
Amount of Final Disposal Amount of waste finally disposed of by landfill out of the total amount of waste generated
Final Disposal Rate Percentage of waste finally disposed of to the total amount of waste generated
Amount of Hazardous Waste Generated Amount of hazardous waste (waste classified as specially-controlled industrial waste generated) out of the total amount of waste generated
Amount of Hazardous Waste Recycled Amount of hazardous waste reused, recycled, or converted into valuable resources out of the total amount of hazardous waste generated
PRTR Substances Non-consolidated Atmospheric emission of PRTR substances that we reported under the PRTR Law
Waste Containing High Levels of PCB in Storage Non-consolidated Total amount/number of waste containing high levels of PCB in storage
Waste Containing Low Levels of PCB in Storage or in Use Total number of devices containing low levels of PCB that are stored or continuously used

●Other Indicators

・The data are basically on a non-consolidated basis.